In a strategic move to improve outcomes for breast cancer patients, Affidea , a leading pan-European provider of community clinics, specialty services and advanced diagnostics, proudly announces that it has selected b-rayZ, a leader in AI-based breast imaging solutions, as its preferred AI partner for breast imaging.

Breast cancer diagnosis often suffers from fragmentation, with critical information scattered across different modalities and specialists. This can slow decision-making and delay life-saving treatments. b-rayZ's AI-powered platform is designed to eliminate these gaps, ensuring a seamless diagnostic pathway that improves both clinical accuracy and therapeutic options for women. By choosing b-rayZ as its AI partner, Affidea is taking a decisive step toward making precision medicine a reality, diagnosis by diagnosis.

The b-rayZ solution is already in use at Affidea Switzerland, at the Affidea Breast Cancer Center of Excellence, Brust Zentrum Zurich, and at Affidea Givision, Site Hôpital Daler. The technology has also been successfully implemented in other countries, including Affidea Lithuania and Affidea Spain, and is planned for expansion to other Affidea markets offering breast imaging services. These initial installations reflect a growing interest and confidence in b-rayZ's ability to standardize and elevate diagnostic quality in diverse clinical settings. With the implementation of this innovative AI solution, Affidea strengthens its commitment to early detection and improved outcomes in breast cancer across Europe.

Affidea has also partnered with b-rayZ as a strategic investor in its Series A capital round. This investment marks an important milestone in b-rayZ's journey and validates its growth vision and strategy. The partnership strengthens b-rayZ's position in the industry and opens the door to valuable collaboration opportunities to accelerate product development, expand into new markets, and enhance its customer offering.

Cristina Rossi, CEO and Founder of b-rayZ, says: “At b-rayZ, we are deeply committed to women’s health. Every woman’s journey after a breast cancer diagnosis is unique, and our AI solutions are designed to provide the highest level of diagnostic accuracy and efficiency, while also being tailored to each woman’s needs. Being selected by Affidea as an AI partner is a testament to our shared vision to transform breast cancer diagnostics. Affidea’s investment in our Series A round further reaffirms this alignment and fuels our growth ambition. Through this strategic partnership, we combine our technological expertise with Affidea’s extensive clinical network to ensure that women across Europe receive faster, more accurate, and personalized breast imaging solutions.”

Dr. Charles Niehaus, Deputy CEO of Affidea, highlights the broader strategic impact of the partnership: “ This collaboration with b-rayZ represents much more than simply the adoption of AI. It is a strategic alliance aimed at redefining breast cancer diagnosis. Together, we plan to expand our collaboration to further develop AI solutions, empower radiologists, optimize clinical workflows, and improve patient care. This partnership, both strategic and financial, puts us on the right path to accelerate innovation across our network. By integrating AI across our network, we ensure that women across Europe receive the most accurate and early diagnoses possible, tailored to them, reinforcing our goal of setting new standards in patient care.”

Dr. Alessandro Roncacci, Senior Vice President and Chief Medical Officer at Affidea, adds: “Breast imaging is a highly specialized field that requires precision, expertise, and the ability to interpret complex data. AI-powered solutions, such as those developed by b-rayZ, are revolutionizing breast cancer diagnostics by increasing radiologists’ capabilities and ensuring greater consistency in cancer detection. Through this collaboration, we are integrating AI to enhance our breast imaging subspecialty, increasing diagnostic accuracy and optimizing personalized screening pathways. This represents a significant step forward in delivering earlier diagnoses, reducing variability in interpretations, and ultimately ensuring the best possible clinical outcomes for women across Europe.”

 

Source: globenewswire.com

Report Abuse